An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus.
Feil, S.C., Hamilton, S., Krippner, G.Y., Lin, B., Luttick, A., McConnell, D.B., Nearn, R., Parker, M.W., Ryan, J., Stanislawski, P.C., Tucker, S.P., Watson, K.G., Morton, C.J.(2012) ACS Med Chem Lett 3: 303-307
- PubMed: 24900468 
- DOI: 10.1021/ml2002955
- Primary Citation of Related Structures:  
3VDD - PubMed Abstract: 
Respiratory infections caused by human rhinovirus are responsible for severe exacerbations of underlying clinical conditions such as asthma in addition to their economic cost in terms of lost working days due to illness. While several antiviral compounds for treating rhinoviral infections have been discovered, none have succeeded, to date, in reaching approval for clinical use ...